S-ClassAbout S-Class
S
SNDXAI Stock Diagnostic Report
Syndax sees Revuforj U.S. peak net revenue in excess of $2B as Q4 axatilimab readouts approach
Syndax's Revuforj and Niktimvo sales are surging, with projections indicating peak revenues of over $200 million in the future, which is expected to have a positive impact on the stock price.
View Source Article ↗AI CATALYST SCORE88 / 100Score computed by Sentinel V12
REFERENCE PRICE$19.08Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support18.64
Near-Term Resistance25.24
02
FUNDAMENTALS
Financial & Fundamental Analysis
Revuforj and Niktimvo have each surpassed annual sales of $200 million, with the CEO emphasizing that these drugs could grow to over $2 million annually. This represents a significant financial performance that greatly enhances growth expectations in the market.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The RSI is at 14.3, indicating an oversold condition. There is a high possibility of a rebound at the support level of 18.64; however, a breakout above the resistance level of 25.24 is necessary for a reversal.
Support18.64
Resistance25.24
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
As the announcement of Q4 axatilimab clinical results approaches, market interest in the commercial success potential of axatilimab is intensifying. If axatilimab shows a growth trajectory similar to Revuforj/Niktimvo, there may be significant upside potential relative to its market capitalization.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-05)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.